Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE plus Ivonescimab for unresectable non-metastatic hepatocellular carcinoma
ChiCTR2500104576Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- Jun 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivonescimab in hepatocellular carcinoma (HCC), sponsored by Huashan Hospital. Primary endpoint: Objective response rate (ORR). Started Jun 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500104576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104576.